• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

    7.540 +0.080 (+1.07%)
    Streaming Delayed Price Updated: 3:03 PM EST, Jan 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 117,535
    Open 7.480
    Bid (Size) 7.520 (100)
    Ask (Size) 7.540 (400)
    Prev. Close 7.460
    Today's Range 7.440 - 7.570
    52wk Range 7.380 - 30.36
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    FRIDAY DEADLINE: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors to Inquire About a Securities Fraud Class Action by January 9, 2026
    From Berger Montague
    Via GlobeNewswire
    News headline image
    TLX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
    From The Rosen Law Firm PA
    Via GlobeNewswire

    Performance

    YTD
    -1.0%
    -1.0%
    1 Month
    -22.0%
    -22.0%
    3 Month
    -24.2%
    -24.2%
    6 Month
    -51.9%
    -51.9%
    1 Year
    -51.7%
    -51.7%

    More News

    Read More
    News headline image
    TELIX URGENT CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights Before January 9th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    UPCOMING DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    TLX DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Telix Pharmaceuticals
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    TLX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Robbins LLP Reminds Telix Pharmaceuticals Ltd. Stockholders About the January 9, 2026 Lead Plaintiff Deadline – Contact Us Today for Information About the TLX Class Action
    From Robbins LLP
    Via Business Wire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    TELIX CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    TLX Class Action Reminder: Telix Pharmaceuticals Ltd. Stockholders Should Contact Robbins LLP for Information About Leading the Class Action Against TLX
    From Robbins LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Investors of Telix, Freeport, and Primo Brands to Contact the Firm About their Rights Before Lead Plaintiff Deadlines
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
    Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
    What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
    Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
    The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
    What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
    The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 7.540
    When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
    The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 01/07/26 03:03 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.